Immunoglobulin E (IgE) Allergy Blood Tests Market Report 2026

The immunoglobulin e (ige) allergy blood tests market size has grown strongly in recent years. It will grow from $36.06 billion in 2025 to $39.11 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to rising prevalence of allergic diseases, increased awareness of food and environmental allergies, wider availability of elisa-based ige tests, growth of diagnostic laboratory infrastructure, improved clinical guidelines for allergy diagnosis.

The immunoglobulin e (ige) allergy blood tests market size is expected to see strong growth in the next few years. It will grow to $51.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to growing demand for precision allergy diagnostics, increasing adoption of automated and digital immunoassay platforms, rising pediatric and geriatric allergy burden, expansion of allergy testing in emerging markets, integration of ai-driven diagnostic interpretation. Major trends in the forecast period include increasing adoption of allergy-specific blood diagnostics, growing demand for multiplex and high-throughput allergy testing, rising shift from skin prick tests to blood-based ige testing, expansion of point-of-care and automated allergy testing systems, increasing use of allergy profiling for personalized treatment.

The rising prevalence of allergies is expected to drive growth in the IgE allergy blood tests market. Allergies occur when the immune system overreacts to substances that are typically harmless, resulting in symptoms such as sneezing, itching, or respiratory issues. Factors contributing to the increase in allergy cases include lifestyle changes, environmental pollution, and genetic predisposition. IgE allergy blood tests help identify specific allergens by measuring Immunoglobulin E (IgE) antibody levels in the blood, supporting the diagnosis and management of allergic conditions like asthma, allergic rhinitis, and food allergies. For instance, in May 2024, the Food Standards Agency in the UK reported that approximately 6% of the adult population, around 2.4 million people, had a clinically confirmed food allergy. Therefore, the rising prevalence of allergies is fueling the growth of the IgE allergy blood tests market.

Major companies in the IgE allergy blood tests market are focusing on developing AI-powered diagnostic tests to improve accuracy, efficiency, and scalability in allergy detection. These AI-enhanced tests analyze allergy-related data using artificial intelligence and machine learning to provide deeper insights into individual allergic sensitivities, identify patterns, and predict potential reactions. For example, in May 2023, Dr. Dangs Lab, an India-based diagnostic laboratory, introduced 'Allergynius Dx,' a molecular allergy diagnostic test based on microarray technology using nanoparticles, capable of analyzing 163 food and respiratory allergens. This innovation represents a significant advancement in comprehensive allergy testing and management.

In June 2023, Mars, Incorporated, a US-based veterinary health company, acquired Heska Corporation for an undisclosed amount. This acquisition gives Mars access to Heska’s veterinary diagnostics portfolio, including point-of-care diagnostic instruments and allergen-specific IgE testing panels such as Allercept, enhancing its in-clinic diagnostic capabilities, operational scale, and market reach. Heska Corporation is a US-based provider of veterinary diagnostics, imaging, and allergy and immunotherapy solutions, recognized for its specialized IgE testing technology and strong presence in veterinary practices.

Major companies operating in the immunoglobulin e (ige) allergy blood tests market are Roche Holdings Inc., Thermo Fisher Scientific Inc, Abbott Laboratories, Siemens Healthineers Pvt Ltd, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Beckman Coulter Inc., Bio-Rad Laboratories Inc., Randox Laboratories Ltd, Omega Diagnostics Plc, AESKU Group GmbH, HYCOR Biomedical LLC.

North America was the largest region in the immunoglobulin E (IgE) allergy blood tests market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulin e (ige) allergy blood tests market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunoglobulin e (ige) allergy blood tests market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the immunoglobulin e allergy blood tests market by increasing costs of imported diagnostic analyzers, reagents, assay kits, and electronic components used in automated immunoassay systems. These impacts are most evident in regions dependent on imported diagnostic technologies, particularly parts of asia-pacific and latin america. However, tariffs are also encouraging local manufacturing of diagnostic kits and reagents, fostering regional self-reliance and supporting long-term supply chain resilience.

The immunoglobulin e (ige) allergy blood tests market research report is one of a series of new reports that provides immunoglobulin e (ige) allergy blood tests market statistics, including immunoglobulin e (ige) allergy blood tests industry global market size, regional shares, competitors with a immunoglobulin e (ige) allergy blood tests market share, detailed immunoglobulin e (ige) allergy blood tests market segments, market trends and opportunities, and any further data you may need to thrive in the immunoglobulin e (ige) allergy blood tests industry. This immunoglobulin e (ige) allergy blood tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Immunoglobulin E (IgE) allergy blood tests detect and measure IgE antibodies in the blood, which are produced by the immune system in response to allergens. These tests help identify the specific allergens responsible for triggering allergic reactions in individuals. Healthcare professionals use these results to determine the causes of allergic symptoms and develop personalized treatment plans, improving patient management and quality of life.

The main product types in the IgE allergy blood tests market include assays and testing kits, such as enzyme-linked immunosorbent assay (ELISA) kits, fluorescent enzyme immunoassay (FEIA) kits, and chemiluminescent immunoassay (CLIA) kits. These assays and kits comprise the tools and reagents required to analyze biological samples for specific allergens or conditions. They are applied across a variety of areas, including aeroallergens, indoor allergens, outdoor allergens, food allergens, venoms, drug allergies, and latex/metal allergies. The end users of these products include diagnostic laboratories, specialty clinics, hospitals, and research or academic centers, covering a wide spectrum of healthcare and scientific institutions.

The immunoglobulin E (IgE) allergy blood tests market consists of sales of custom panels, and component-resolved diagnostics (CRD). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.